Mehta Analysis: Can Trump Trigger Triple Cascade?
Trump says the biopharma industry can no longer depend on the higher US profit margins with his initiative to peg US drug prices to global norms. The US president needs second and third initiatives to be successful: Enable the regulators and biopharma industry to rationalize R&D, and to eliminate selling costs that collectively account for one-half of the industry, writes Viren Mehta, founding partner of Mehta Partners LLC.
You may also be interested in...
Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.
As it enters a potentially golden decade, can biopharma seize the opportunity to overhaul its business model – and its reputation? Viren Mehta of Mehta Partners LLC discusses.
Industry has the tools to bring more and far better treatments to more people faster than ever, with much lower R&D cost and very little selling needed for these targeted therapies – a perfect prescription for slashing prices for global access while preserving profits, argues Viren Mehta of Mehta Partners LLC.